How Sarcopenia, Muscle Mass, Strength, and Performance Relate to Non-Alcoholic Fatty Liver Disease: A Systematic Review
Background and aim: Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD) affects up to 25% of the population and causes significant morbidity and mortality. Sarcopenia, the loss of muscle strength and quantity/quality, shares...
Saved in:
| Main Authors: | Joana Rigor, Matilde Monteiro-Soares, Pedro Barata, Daniela Martins-Mendes |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-10-01
|
| Series: | Sci |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2413-4155/6/4/59 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Biomarkers for sarcopenia, muscle mass, muscle strength, and physical performance: an umbrella review
by: Gaoming Liu, et al.
Published: (2025-06-01) -
Features of Management of Patients with NAFLD and Sarcopenia
by: M. E. Statsenko, et al.
Published: (2025-05-01) -
Modern views on the management tactics of patients with sarcopenia in combination with non-alcoholic fatty liver disease
by: V. A. Akhmedov, et al.
Published: (2024-08-01) -
Short‐chain fatty acids enhance muscle mass and function through the activation of mTOR signalling pathways in sarcopenic mice
by: Chaoran Liu, et al.
Published: (2024-12-01) -
Ultrasound assessment of muscle mass in the diagnosis of sarcopenia in cardiovascular patients
by: A. S. Erokhina, et al.
Published: (2021-05-01)